Treatment with idelalisib in patients with chronic lymphocytic leukemia – real world data from the registry of the German CLL Study Group

Idelalisib in combination with rituximab is an efficacious treatment for patients suffering from chronic lymphocytic leukemia (CLL) with known limitations due to toxicities. However, the benefit after prior Bruton tyrosine kinase inhibitor (BTKi) therapy remains unclear. For this analysis, 81 patien...

Descripción completa

Detalles Bibliográficos
Autores principales: von Tresckow, Julia, Heyl, Nikola, Robrecht, Sandra, Giza, Adam, Aldaoud, Ali, Schlag, Rudolf, Klausmann, Martine, Linde, Hartmut, Stein, Wolfgang, Schwarzer, Andreas, Fischer, Kirsten, Cramer, Paula, Eichhorst, Barbara, Hallek, Michael, Fink, Anna Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567876/
https://www.ncbi.nlm.nih.gov/pubmed/37358640
http://dx.doi.org/10.1007/s00277-023-05314-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567876/
https://www.ncbi.nlm.nih.gov/pubmed/37358640
http://dx.doi.org/10.1007/s00277-023-05314-2

Ejemplares similares